Table 1.
Levofloxacin-based first-line treatment regimens in H. pylori infection.
| First author Year | Study design | Patients (n) | Regimens | Treatment duration (days) | Eradication rates, intention to treat (%) (n) | Side effects (%) |
|---|---|---|---|---|---|---|
| Cammarota [2000] | Prospective randomized | 100 | RAB 20 mg od, LEV 500 mg od, AMO 1000 mg bid | 7 | 92 (46/50) | 8 |
| RAB 20 mg od, LEV 500 mg od, TIN 500 mg bid | 90 (45/50) | 10 | ||||
| Di Caro et al. [2002b] | Prospective | 160 | RAB 20 mg od, LEV 500 mg od | 5 | 50 (20/40) | 0 |
| randomized | RAB 20 mg od, LEV 500 mg od | 7 | 70 (28/40) | 0 | ||
| RAB 20 mg od, LEV 500 mg od | 10 | 65 (26/40) | 15 | |||
| RAB 20 mg od, LEV 500 mg od, AMO 1000 mg bid | 7 | 90 (36/40) | 30 | |||
| Iacopini [2005] | Prospective | 164 | ESO 20 mg od, LEV 500 mg od, AZI 500 mg od | 7 | 65 (54/83) | 12 |
| randomized | ESO 20 mg bid, CLA 500 mg bid, AMO 1000 mg bid | 7 | 65 (53/81) | 30 | ||
| Nista [2006] | Prospective randomized | 300 | ESO 20 mg bid, CLA 500 mg bid, AMO 1000 mg bid | 7 | 75 (75/100) | 20 |
| ESO 20 mg bid, CLA 500 mg bid, MET 500 mg bid | 7 | 72 (72/100) | 18 | |||
| ESO 20 mg bid, CLA 500 mg bid, LEV 5000 mg bid | 7 | 87 (87/100) | 13 | |||
| Antos [2006] | Prospective randomized | 61 | ESO 40 mg bid, LEV 500 mg bid, AMO 1000 mg bid | 7 | 87 (26/30) | 52 |
| ESO 20 mg bid, CLA 500 mg bid, AMO 1000 mg bid | 7 | 84 (26/31) | 41 | |||
| Gisbert [2007] | Prospective | 64 | RBC 400 mg bid, LEV 500 mg bid, AMO 1000 mg bid | 10 | 84 (54/64) | 10 |
| Rispo [2007] | Prospective randomized | 130 | ESO 20 mg bid, LEV 250 mg bid, AMO 1000 mg bid | 7 | 91 (59/65) | * |
| ESO 20 mg bid, CLA 500 mg bid, AMO 1000 mg bid | 7 | 77 (50/65) | ||||
| Schrauwen [2009] | Prospective | 104$ | ESO 40 mg bid, LEV 500 mg bid, AMO 1000 mg bid | 7 | 96 (43/45)$ | 29‡ |
| ESO 40 mg bid, LEV 500 mg bid, CLA 500 mg bid | 7 | 93 (55/59)$ | 41‡ | |||
| Castro-Fernández [2009] | Prospective | 135 | OME 20 mg bid§, LEV 500 mg bid, AMO 1000 mg bid | 10 | 72 (97/135) | 12 |
| Gisbert [2009] | Prospective | 75 | OME 20 mg bid, LEV 500 mg bid, AMO 1000 mg bid | 10 | 83 (62/75) | 13 |
| Molina-Infante [2010] | Prospective randomized | 460 | OME 20 mg bid, CLA 500 mg bid, AMO 1000 mg bid | 10 | 64 (74/115) | 25 |
| OME 20 mg bid, LEV 500 mg bid, AMO 1000 mg bid | 10 | 80 (93/115) | 27 | |||
| OME 20 mg bid (1–10), AMO 1000 mg bid (1–5), | 10 | 77 (88/115) | 25 | |||
| CLA 500 mg bid (6–10), MET 500 mg bid (6–10) | ||||||
| OME 20 mg bid (1–10), AMO 1000 mg bid (1–5), | 10 | 83 (95/115) | 25 | |||
| LEV 500 mg bid (6–10), MET 500 mg bid (6–10) | ||||||
| Liou [2010] | Prospective randomized | 432 | LAN 30 mg bid, LEV 750 mg od, AMO 1000 mg bid | 7 | 74 (161/217) | * |
| LAN 30 mg bid, CLA 500 mg bid, AMO 1000 mg bid | 7 | 84 (180/215) |
*
No data; $only data from first-line therapies; ‡data allowing no discrimination between first- and second-line; §or other PPI bid.
AMO, amoxicillin; AZI, azithromycin; bid, twice daily; CLA, clarithromycin; ESO, esomeprazole; LAN, lansoprazole; LEV, levofloxacin; MET, metronidazole; od, once daily; OME, omeprazole; RAB, rabeprazole; RBC, ranitidine bismuth citrate; TIN, tinidazole.